Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

600
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
Drug Therapy01:28

Drug Therapy

449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
449
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Methods of reducing fever01:22

Methods of reducing fever

1.6K
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A potent and manipulable graft-<i>versus</i>-leukemia effect underpins the increasingly important role of transplantation in acute myeloid leukemia.

Haematologica·2026
Same author

Initial leukemic epigenomic state determines hypomethylating agent response.

Nature communications·2026
Same author

Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.

British journal of haematology·2026
Same author

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.

Bone marrow transplantation·2025
Same author

Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.

The Lancet. Oncology·2025
Same author

Guidance for <i>JCO</i> Authors on Subgroup Representation and Reporting.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Pharmacological methods to reduce disease recurrence.

Charles Craddock1

  • 11Queen Elizabeth Hospital, Birmingham, United Kingdom.

Hematology. American Society of Hematology. Education Program
|December 10, 2013
PubMed
Summary
This summary is machine-generated.

Allogeneic stem cell transplants offer hope for high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). New strategies focus on reducing relapse and improving outcomes by optimizing conditioning regimens and graft-versus-leukemia effects.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

825

Related Experiment Videos

Last Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

825

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Allogeneic stem cell transplantation is a key treatment for high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • Despite reduced transplant-related mortality (TRM), disease relapse remains the primary cause of treatment failure.
  • An inverse correlation exists between relapse risk and TRM, necessitating balanced approaches.

Purpose of the Study:

  • To explore novel conditioning strategies for maximizing antitumor activity while minimizing toxicity in AML and MDS.
  • To investigate methods for optimizing the graft-versus-leukemia (GVL) effect to reduce disease relapse.
  • To evaluate adjunctive posttransplantation therapies for augmenting antileukemic activity.

Main Methods:

  • Development of novel reduced-intensity conditioning regimens tailored for high-risk AML and MDS.
  • Strategies to optimize the graft-versus-leukemia (GVL) effect, including minimizing immunosuppression and donor lymphocyte infusions.
  • Investigation of adjunctive posttransplantation therapies to enhance anti-leukemic responses.

Main Results:

  • Novel conditioning regimens are being developed to balance efficacy and toxicity.
  • Optimizing GVL effects and employing adjunctive therapies show promise in reducing relapse.
  • Advances in drug delivery and design support new therapeutic strategies.

Conclusions:

  • Recent advances offer a realistic possibility of improving outcomes for patients undergoing allogeneic stem cell transplantation for high-risk AML and MDS.
  • Balancing conditioning intensity, GVL effects, and posttransplantation therapies is crucial.
  • Further research into novel strategies holds significant potential for enhancing treatment success.